

Corporate Factsheet

April 2025

Company Profile

OrbusNeich is a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures. Headquartered in Hong Kong, China, OrbusNeich sells its products in more than 70 countries and regions worldwide. It is also actively expanding into neuro vascular intervention and structural heart disease. OrbusNeich is listed on the Main Board of the Hong Kong Stock Exchange under the stock code 6929.

Employees worldwide

 **1300+**

Leadership

 **20+** Years of experience


Core management team

Innovation

 **240+**

Granted patents & patent applications globally

Bases

 **2** R&D facilities
3 Production centers

Capacity

 **2** million balloons & **60** thousand stents

Annual production capacity

Sales network

 **70+**

Countries & regions

Excellent capabilities in R&D, Operation and Commercialization

R&D

R&D development

- Over 240 granted patents and patent applications globally
- Completed Scoreflex TRIO clinical trial patient enrollment in China
- Initiated patient enrollment for the Sapphire 3 clinical trial in the US

Product approval

- FDA: Teleport XT, JADE Plus 14/18/35 OTW, Sapphire Ultra, Sapphire NC Ultra
- CE: Sapphire Ultra, Sapphire NC Ultra, Xtenza and Teleport XT
- NMPA: Teleport Neuro

Operation


- Passed the audits and inspections by NMPA, FDA, PMDA and NB for the QMS
- Obtained ISO 13485, ISO14001 & ISO 45001

Latest developments:

- Started constructing the group's largest R&D and manufacturing base in Hangzhou, China

Commercialization

- Sales network covering over 70 countries and regions
- Direct and distributor sales accounted for 58% and 42% of total sales in FY 2024 respectively
- Held or participated in around 80 seminars, workshops, conferences, discussion panels and Physician Exchange Program globally in FY 2024



Headquarters
Hong Kong, China



R&D and Production Center
Shenzhen, China



EU Regional Headquarters & Production Center
Hoevelaken, the Netherlands




Production Center
Weil am Rhein, Germany



Advanced Technology Laboratory
Tokyo, Japan

Product portfolio





As of December 31, 2024

	Lesion Access	Lesion Preparation	Lesion Therapy	Lesion Optimization
PCI	<div> Teleport SAPPHIRE[®] 3 SAPPHIRE[®] II PRO EZGuide[™]</div>	<div>SAPPHIRE[®] II PRO SAPPHIRE[®] 3 scoreflex[®] NC scoreflex[®] TRIO[®] Teleport</div>	<div>COMBO[®] PLUS eucaLIMUS SUPPORT C</div>	<div>SAPPHIRE[®] NC 24</div>
PTA	<div> Teleport SAPPHIRE[®] II PRO</div>	<div>JADE[®] scoreflex[®] PTA Teleport</div>	<div>RESISTANT[™] VITUS</div>	<div>JADE[®]</div>

Key Financial Figures

Breakdown of revenue for FY 2024



Corporate Headquarters

Address | Units 303 & 305, 3/F, Building 20E, Hong Kong Science Park, Shatin, N.T. Hong Kong
Phone | +852 2802 2288 Email | pr@orbusneich.com

www.OrbusNeich.com